Aardvark Therapeutics Inc
AARD14.550USD
+0.780+5.66%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
316.39MMarket Cap
LossP/E TTM
More Details of Aardvark Therapeutics Inc Company
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Aardvark Therapeutics Inc Info
Ticker SymbolAARD
Company nameAardvark Therapeutics Inc
IPO dateFeb 13, 2025
CEOLee (Tien-Li)
Number of employees22
Security typeOrdinary Share
Fiscal year-endFeb 13
Address4370 La Jolla Village Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92122
Phone18582257696
Websitehttps://aardvarktherapeutics.com/
Ticker SymbolAARD
IPO dateFeb 13, 2025
CEOLee (Tien-Li)
Company Executives of Aardvark Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Tien-Li Lee, M.D.
Dr. Tien-Li Lee, M.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.54M
+0.08%
Dr. Bryan Jones, Ph.D.
Dr. Bryan Jones, Ph.D.
Chief Operating Officer
Chief Operating Officer
1.25K
--
Dr. Chien Chuen Chien Chuen (Jeffrey) Chi, Ph.D.
Dr. Chien Chuen Chien Chuen (Jeffrey) Chi, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Ms. Susan E. Graf
Ms. Susan E. Graf
Independent Director
Independent Director
--
--
Mr. Victor Tong, Jr.
Mr. Victor Tong, Jr.
Independent Director
Independent Director
--
--
Mr. Nelson B. Sun
Mr. Nelson B. Sun
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Manasi Jaiman, M.D.
Dr. Manasi Jaiman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy Kieffer, Ph.D.
Mr. Timothy Kieffer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Danny Villeneuve
Mr. Danny Villeneuve
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Tien-Li Lee, M.D.
Dr. Tien-Li Lee, M.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.54M
+0.08%
Dr. Bryan Jones, Ph.D.
Dr. Bryan Jones, Ph.D.
Chief Operating Officer
Chief Operating Officer
1.25K
--
Dr. Chien Chuen Chien Chuen (Jeffrey) Chi, Ph.D.
Dr. Chien Chuen Chien Chuen (Jeffrey) Chi, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Ms. Susan E. Graf
Ms. Susan E. Graf
Independent Director
Independent Director
--
--
Mr. Victor Tong, Jr.
Mr. Victor Tong, Jr.
Independent Director
Independent Director
--
--
Mr. Nelson B. Sun
Mr. Nelson B. Sun
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Decheng Capital LLC
17.99%
Vickers Venture Partners
9.42%
Lee (Tien-Li)
7.13%
Lee (Jane Wu)
6.77%
Citadel Advisors LLC
6.25%
Other
52.45%
Shareholders
Shareholders
Proportion
Decheng Capital LLC
17.99%
Vickers Venture Partners
9.42%
Lee (Tien-Li)
7.13%
Lee (Jane Wu)
6.77%
Citadel Advisors LLC
6.25%
Other
52.45%
Shareholder Types
Shareholders
Proportion
Venture Capital
27.41%
Hedge Fund
17.13%
Individual Investor
14.55%
Investment Advisor
5.53%
Investment Advisor/Hedge Fund
2.45%
Research Firm
0.59%
Bank and Trust
0.03%
Pension Fund
0.02%
Other
32.28%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
83
11.58M
45.10%
+46.56K
2025Q3
80
11.53M
45.26%
+548.92K
2025Q2
65
10.97M
40.04%
+235.22K
2025Q1
29
10.74M
23.81%
+5.57M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Decheng Capital LLC
3.92M
18.05%
--
--
Jun 30, 2025
Vickers Venture Partners
2.05M
9.45%
+2.05M
--
Feb 13, 2025
Lee (Tien-Li)
1.54M
7.11%
+30.00K
+1.98%
Sep 15, 2025
Lee (Jane Wu)
1.47M
6.79%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.28M
5.92%
+9.65K
+0.76%
Jun 30, 2025
Laurion Capital Management LP
989.07K
4.56%
+180.82K
+22.37%
Jun 30, 2025
The Vanguard Group, Inc.
460.98K
2.12%
+295.49K
+178.55%
Jun 30, 2025
Adage Capital Management, L.P.
175.00K
0.81%
-75.00K
-30.00%
Jun 30, 2025
SilverArc Capital Management, LLC
286.81K
1.32%
+167.31K
+140.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aardvark Therapeutics Inc?
The top five shareholders of Aardvark Therapeutics Inc are:
Decheng Capital LLC holds 3.92M shares, accounting for 18.05% of the total shares.
Vickers Venture Partners holds 2.05M shares, accounting for 9.45% of the total shares.
Lee (Tien-Li) holds 1.54M shares, accounting for 7.11% of the total shares.
Lee (Jane Wu) holds 1.47M shares, accounting for 6.79% of the total shares.
Citadel Advisors LLC holds 1.28M shares, accounting for 5.92% of the total shares.
Decheng Capital LLC holds 3.92M shares, accounting for 18.05% of the total shares.
Vickers Venture Partners holds 2.05M shares, accounting for 9.45% of the total shares.
Lee (Tien-Li) holds 1.54M shares, accounting for 7.11% of the total shares.
Lee (Jane Wu) holds 1.47M shares, accounting for 6.79% of the total shares.
Citadel Advisors LLC holds 1.28M shares, accounting for 5.92% of the total shares.
What are the top three shareholder types of Aardvark Therapeutics Inc?
The top three shareholder types of Aardvark Therapeutics Inc are:
Decheng Capital LLC
Vickers Venture Partners
Lee (Tien-Li)
Decheng Capital LLC
Vickers Venture Partners
Lee (Tien-Li)
How many institutions hold shares of Aardvark Therapeutics Inc (AARD)?
As of 2025Q4, 83 institutions hold shares of Aardvark Therapeutics Inc, with a combined market value of approximately 11.58M, accounting for 45.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.16%.
What is the biggest source of revenue for Aardvark Therapeutics Inc?
In --, the -- business generated the highest revenue for Aardvark Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
